Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders

被引:146
作者
Viollet, B. [1 ,2 ]
Mounier, R. [1 ,2 ]
Leclerc, J. [1 ,2 ]
Yazigi, A. [3 ]
Foretz, M. [1 ,2 ]
Andreelli, F. [1 ,2 ,3 ]
机构
[1] Univ Paris 05, Inst Cochin, CNRS, UMR 8104,Dept Endocrinol Metab & Canc, Paris, France
[2] INSERM, U 567, Paris, France
[3] INSERM, U 695, IFR Xavier Bichat, Paris, France
关键词
energy metabolism; type; 2; diabetes; review;
D O I
10.1016/j.diabet.2007.10.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the light of recent studies in humans and rodents, AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase, has been described as an integrator of regulatory signals monitoring systemic and cellular energy status. AMP-activated protein kinase (AMPK) has been proposed to function as a 'fuel gauge' to monitor cellular energy status in response to nutritional environmental variations. Recently, it has been proposed that AMPK could provide a link in metabolic defects underlying progression to the metabolic syndrome. AMPK is a heterotrimerie enzyme complex consisting of a catalytic subunit a and two regulatory subunits beta and gamma. AMPK is activated by rising AMP and falling ATP. AMP activates the system by binding to the gamma subunit that triggers phosphorylation of the catalytic a subunit by the upstream kinases LKB1 and CaMKK beta (calmodulin-dependent protein kinase kinase). AMPK system is a regulator of energy balance that, once activated by low energy status, switches on ATP-producing catabolic pathways (such as fatty acid oxidation and glycolysis), and switches off ATP-consuming anabolic pathways (such as lipogenesis), both by short-term effect on phosphorylation of regulatory proteins and by long-term effect on gene expression. As well as acting at the level of the individual cell, the system also regulates food intake and energy expenditure at the whole body level, in particular by mediating the effects of insulin sensitizing adipokines leptin and adiponectin. AMPK is robustly activated during skeletal muscle contraction and myocardial ischaemia playing a role in glucose transport and fatty acid oxidation. In liver, activation of AMPK results in enhanced fatty acid oxidation as well as decreased glucose production. Moreover, the AMPK system is one of the probable targets for the anti-diabetic drugs biguanides and thiazolidinediones. Thus, the relationship between AMPK activation and beneficial metabolic effects provide the rationale for the development of new therapeutic strategies in metabolic disorders. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 39 条
[1]   Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin [J].
Andreelli, F ;
Foretz, M ;
Knauf, C ;
Cani, PD ;
Perrin, C ;
Iglesias, MA ;
Pillot, B ;
Bado, A ;
Tronche, F ;
Mithieux, G ;
Vaulont, S ;
Burcelin, R ;
Viollet, B .
ENDOCRINOLOGY, 2006, 147 (05) :2432-2441
[2]   Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats [J].
Bergeron, R ;
Previs, SF ;
Cline, GW ;
Perret, P ;
Russell, RR ;
Young, LH ;
Shulman, GI .
DIABETES, 2001, 50 (05) :1076-1082
[3]   Thiazolidinediones, like metformin, inhibit respiratory complex I -: A common mechanism contributing to their antidiabetic actions? [J].
Brunmair, B ;
Staniek, K ;
Gras, F ;
Scharf, N ;
Althaym, A ;
Clara, R ;
Roden, M ;
Gnaiger, E ;
Nohl, H ;
Waldhäusl, W ;
Fürnsinn, C .
DIABETES, 2004, 53 (04) :1052-1059
[4]   Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients [J].
Carey, DG ;
Cowin, GJ ;
Galloway, GJ ;
Jones, NP ;
Richards, JC ;
Bisivas, N ;
Doddrell, DM .
OBESITY RESEARCH, 2002, 10 (10) :1008-1015
[5]   Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome [J].
Cool, Barbara ;
Zinker, Bradley ;
Chiou, William ;
Kifle, Lemma ;
Cao, Ning ;
Perham, Matthew ;
Dickinson, Robert ;
Adler, Andrew ;
Gagne, Gerard ;
Iyengar, Rajesh ;
Zhao, Gang ;
Marsh, Kennan ;
Kym, Philip ;
Jung, Paul ;
Camp, Heidi S. ;
Frevert, Ernst .
CELL METABOLISM, 2006, 3 (06) :403-416
[6]   AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2α in adipocytes [J].
Dagon, Y ;
Avraham, Y ;
Berry, EM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 340 (01) :43-47
[7]   The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428
[8]   Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver [J].
Foretz, M ;
Ancellin, N ;
Amdreelli, F ;
Saintillan, Y ;
Grondin, P ;
Kahn, A ;
Thorens, B ;
Vaulont, S ;
Viollet, B .
DIABETES, 2005, 54 (05) :1331-1339
[9]   The AMP-activated protein kinase pathway - new players upstream and downstream [J].
Hardie, DG .
JOURNAL OF CELL SCIENCE, 2004, 117 (23) :5479-5487
[10]   Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion [J].
Leclerc, I ;
Woltersdorf, WW ;
Xavier, GD ;
Rowe, RL ;
Cross, SE ;
Korbutt, GS ;
Rajotte, RV ;
Smith, R ;
Rutter, GA .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (06) :E1023-E1031